No Data
No Data
Beijing Konruns Pharmaceutical (603590.SH): Sun Yuping resigned from the position of secretary to the board and financial director.
Beijing Konruns Pharmaceutical (603590.SH) announced that the board of directors recently received a letter from Sun Yu, the secretary of the board of directors and the chief financial officer, stating that he is unable to continue to perform his duties due to personal reasons. The board of directors expressed their respect and understanding, and agreed to Mr. Sun's resignation.
Beijing Konruns Pharmaceutical (603590.SH): Clinical research results of the innovative traditional Chinese medicine ZY5301 made it into the sub-journal of JAMA.
On July 29, Gelonhui announced that ZY5301 is a traditional Chinese medicine innovative drug with independent intellectual property rights owned by Beijing Konruns Pharmaceutical Co., Ltd., focusing on the clinical research of chronic pelvic pain after female pelvic inflammatory disease. Recently, the Phase II clinical study results of ZY5301 (CTR20202153) were officially accepted and published in JAMANetworkOpen after rigorous evaluation by multiple international review experts.
Beijing Konruns Pharmaceutical (603590.SH) granted 0.66 million restricted stocks to 14 incentive targets.
Beijing Konruns Pharmaceutical (stock code 603590.SH) has announced that the board of directors has approved the company's restricted stock incentive plan for 2023...
Beijing Konruns Pharmaceutical (603590.SH) renews their house rental contract.
On July 3, Gelonhui reported that Beijing Konruns Pharmaceutical (603590.SH) signed a house rental contract with its affiliate. The contract for the rental property located at Building 4, No.7 Science Park Road, Life Science Park, Changping District, Beijing, will expire on June 30, 2024. In order to ensure the company's research and office needs, the company renewed the house rental contract with Konruns Pharmaceuticals and continued to rent the property at 2-5 floors, Building 4, No. 7 Science Park Road, Life Science Park, Changping District, Beijing. The rental area is 4,015.45 square meters, and the lease term is three years from July 1, 2024 to June 30, 2027.
Beijing Konruns Pharmaceutical (603590.SH) will distribute a dividend of 3 yuan per 10 shares in 2023, with a registration date of July 3rd.
Zhicheng Finance APP News, Beijing Konruns Pharmaceutical (603590.SH) announced that the company will distribute annual equity for the year 2023, with a cash dividend of 3 yuan (including tax) per 10 shares. The record date is July 3.
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
No Data